Peking Union Medical College

Malnutrition in Early Life Sets Stage for Metabolic Disorders, Says New Review in Chinese Medical Journal

Retrieved on: 
Monday, January 24, 2022 - 1:37pm

The general consensus is the onset of metabolic disorders in adult life depends mostly on genetic predisposition and lifestyle.

Key Points: 
  • The general consensus is the onset of metabolic disorders in adult life depends mostly on genetic predisposition and lifestyle.
  • Clinical studies show that inappropriate nutrition during pregnancy and early life can set the stage for metabolic disorders in adulthood.
  • This happens because the fetus or newborn performs a preventive metabolic programming to 'prepare' itself for later in life.
  • Title of original paper: Early-life nutrition and metabolic disorders in later life: a new perspective on energy metabolism

EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and Platform Technologies

Retrieved on: 
Monday, January 24, 2022 - 12:35pm

Under the agreement, both parties will jointly develop hematopoietic stem cell regenerative therapies, including the development of innovative genetically-modified hematopoietic stem cell therapies and the exploration of novel biomarkers to optimize quality control for stem cell production.

Key Points: 
  • Under the agreement, both parties will jointly develop hematopoietic stem cell regenerative therapies, including the development of innovative genetically-modified hematopoietic stem cell therapies and the exploration of novel biomarkers to optimize quality control for stem cell production.
  • Hematopoietic stem cells (HSCs) have the potential for long-term self-renewal and can differentiate into various types of mature blood cells.
  • "This collaboration with Haihe Laboratory of Cell Ecosystem will further our exploration in the field of hematopoietic stem cells.
  • In 2021, EdiGene initiated a Phase I multicenter clinical trial of ET-01, its gene-editing hematopoietic stem cell therapy for transfusion-dependent -thalassemia.

­­­Review in Chinese Medical Journal Explores Effect of Gut Microbiota on Inflammatory Bowel Disease

Retrieved on: 
Tuesday, January 18, 2022 - 1:42pm

"Dysbiosis" or an imbalance in their populations can, however, contribute to the pathology of gastrointestinal diseases such as inflammatory bowel disease (IBD).

Key Points: 
  • "Dysbiosis" or an imbalance in their populations can, however, contribute to the pathology of gastrointestinal diseases such as inflammatory bowel disease (IBD).
  • Researchers from the Peking Union Medical College, China and the Chinese Academy of Medical Sciences have delved deeper into understanding multi-dimensional dysbiosis and technologies that can aid the diagnosis and treatment of IBD.
  • Next, they describe the "mycobiome" or fungal microbiota, that has been relatively less explored, and their interplay with bacterial populations.
  • Finally, the review highlights therapeutic strategies such as "fetal microbiota transplantation" and "supplementary probiotics" that can help replenish gut microbiota and restore balance.

Chinese Medical Journal Study Shows That Rural-to-Urban Migration Can Lead to Obesity

Retrieved on: 
Friday, January 14, 2022 - 1:33pm

This is particularly concerning for public health authorities in China, a country that has seen large-scale rural-to-urban migration as Chinese workers seek out opportunities to better their lives.

Key Points: 
  • This is particularly concerning for public health authorities in China, a country that has seen large-scale rural-to-urban migration as Chinese workers seek out opportunities to better their lives.
  • However, associations between urban living and overweight and obesity have not been well-studied in China.
  • The results of their analyses appear in a paper published in Chinese Medical Journal on 20 August, 2020.
  • Titles of original papers: Association between age at arrival, duration of migration, and overweight/obesity in Chinese rural-to-urban migrants: the Yi migrant study

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

Retrieved on: 
Wednesday, January 12, 2022 - 1:26am

Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.

Key Points: 
  • Safety data on the phase I clinical trial was released by Director Chen Guiling of Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, and the results indicated high safety and well toleration.
  • Compared to the phase I clinical trial results of similar products, it demonstrated excellent safety and immunogenicity.
  • At present, the phase I clinical trials of all 3 China's mRNA vaccines are carried out at the Phase I Clinical Trial Laboratory of Shulan (Hangzhou) Hospital, among which the first mRNA vaccine is already under phase III clinical trial overseas.
  • At the meeting, top-notch experts acclaimed the phase I results of the mRNA COVID-19 vaccine (LVRNA009) of AIM Vaccine.

Medtronic Announces Approval of the Evolut™ PRO TAVR System in China

Retrieved on: 
Monday, January 10, 2022 - 1:00pm

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved the CoreValve™ Evolut™ PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery. As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics (blood flow). Full commercial launch is anticipated in early calendar year 2022.

Key Points: 
  • As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics (blood flow).
  • The Evolut PRO TAVR system is the next generation of the clinically proven supra-annular CoreValve Evolut R system that provides industry-leading hemodynamic performance.
  • "The Evolut PRO TAVR system has shown impressive clinical outcomes and I look forward to seeing it benefit more patients throughout China."
  • The approval is based on data from high- and extreme-risk patients across Medtronic-sponsored studies and real-world registries with the CoreValve Evolut TAVR platform.

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC

Retrieved on: 
Friday, December 10, 2021 - 2:43pm

The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.

Key Points: 
  • The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.
  • Existing domestic and overseas studies have shown that monotherapy or combination chemotherapy of anti-PD-(L)1 monoclonal antibody has already become new standard for the first-line treatment of NSCLC.
  • Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer

Retrieved on: 
Tuesday, November 30, 2021 - 12:30pm

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Phase 3 PRIME study of ZEJULA (niraparib) as maintenance therapy met its primary endpoint. ZEJULA demonstrated a statistically significant and clinically meaningful progression-free survival (PFS) benefit with a tolerable safety profile in Chinese patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) following a response to platinum-based chemotherapy, regardless of biomarker status.

Key Points: 
  • Importantly, the PRIME study further underscores the status of ZEJULA as the first and only PARP inhibitor approved globally, including in China, as monotherapy for all-comer patients in the first-line maintenance treatment settings.
  • The study evaluated the efficacy of ZEJULA as a maintenance treatment, with the primary endpoint of PFS as assessed by blinded independent central review.
  • While platinum-based chemotherapy is effective at inducing an initial response in ovarian cancer, the disease will recur in the majority of women.
  • A Phase 1 pharmacokinetic (PK) study of ZEJULA was conducted in Chinese patients with ovarian cancer.

CASI Pharmaceuti­­­cals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization

Retrieved on: 
Monday, October 25, 2021 - 12:00pm

CASI shares global co-commercial and profit-sharing rights with Juventas and indirectlyowns a 12.0098% equity stake in Juventas on a fully diluted basis following completion of the Series C financing round.

Key Points: 
  • CASI shares global co-commercial and profit-sharing rights with Juventas and indirectlyowns a 12.0098% equity stake in Juventas on a fully diluted basis following completion of the Series C financing round.
  • Dr. Wei-Wu He, CEO and Chairman of CASI comments: "CASI, through its commercialization of Evomela in China, has built a robust commercial team in the hematology-oncology market.
  • The collaboration between CASI and Juventas will speed up the adoption of CAR-T therapy in China, helping thousands of patients in need of this breakthrough therapy."
  • The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China.

Neurophth Expands Its Global Gene Therapy Leadership Team with the Appointment of Dr. Zhengbin Li as Head of Commercial

Retrieved on: 
Thursday, August 19, 2021 - 3:00pm

At Neurophth, he will apply his extensive past experiencein growing and scaling businesses that apply gene therapy technology to Ophthalmology to improve the lives of under-served patients.

Key Points: 
  • At Neurophth, he will apply his extensive past experiencein growing and scaling businesses that apply gene therapy technology to Ophthalmology to improve the lives of under-served patients.
  • Dr. Li's previous positions include commercial leadership roles at top MNC pharmaceuticals including Bristol-Myers Squibb, Sanofi, Bayer, Novartis etc..
  • Within Novartis, he was a member of Lucentis best-in-class launch commercial launchteam as well as global Ophthalmology brand team.
  • Within Bayer, he led the company's successful launch of Eylea, built the commercial team and oversaw the strategic planning for the Ophthalmology business unit.